BioLineRx Files Protocol Amendment to Phase 2 Study for AML Treatment based on Encouraging Efficacy and Strong Safety Profile

The amendment will include the testing of higher doses, resulting in an increase in the total study population to 70 patients. The changes were unanimously recommended by the Clinical Advisory Board.